Table 1 Characteristics of the included studies and participants
From: Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
Study ID | Patients evaluate n (% male) | Median age (years) | Cancer type | Target antigen | Study type (NCT number) | Previous cardiotoxicity | FU duration | NOS score |
|---|---|---|---|---|---|---|---|---|
Brammer et al. [23] | 66 (62%) | 60 (23–80) | Lymphoid malignancies | CD19 | Cohort | NA | NA | 7 |
Brammer et al. [24] | 90 (57.8%) | 61* | R/R Lymphomas | CD19 | Cohort | AF: 10 (11.1%) CHF: 8 (8.9%) CAD: 7 (7.8%) | 16.5 (1–54) months | 8 |
Ganatra et al. [25] | 116 (61%) | 63 (19–80) | R/R ANHL, DLBCL | CD19 | Cohort | Hypertension: 44 (38.6%) CAD: 12 (10.3%) | 6.21 (1–15.7) months | 7 |
Lee et al. [26] | 47 (NA) | NA | NHL | CD19 | Cohort | NA | NA | 5 |
Locke et al. [27] | 277 (65.34%) | 65 | DLBCL,TFL, PMBCL,HGBCL | CD19 | Cohort | NA | 15.4 (13.7–17.3) months | 8 |
Neelapu et al. [28] | 101 (67%) | 58 (23–76) | DLBCL,PMBCL,TFL | CD19 | RCT (NCT02348216) | NA | At least 6 months | NA |
Patel N et al. [29] | 49 (NA) | 68* | Lymphoid malignancies | CD19 | Cohort | NA | NA | 8 |
Schuster et al. [30] | 63 (63.5%) | 65 | NHL, B Cell Lymphomas | CD19 | RCT (NCT02030834) | NA | 29.3 (7.7–37.9) months | NA |
Wudhikarn et al. [31] | 60 (70%) | 62.9 (19.5–85.9) | aggressive B-NHL | CD19 | Cohort | NA | NA | 7 |
Raphael et al. [32] | 165 (72%) | 60 (18–88) | Aggressive B-NHL | CD19 | Cohort | HF: 13 (8%) CAD: 15 (9%) | 16.2 (14.3–19.1) months | 7 |
Ivan et al. [33] | 345 (NA) | NA | NHL | CD19 | Cohort | NA | NA | 7 |